Cefazolin for empiric treatment of HD-related infections: Efficacy and blood concentrations.
ASN 30th Annual Meeting, San Antonio
J Am Soc Nephrol (Sep) 8:202A 1997
Vancomycin is frequently used to treat access infections in hemodialysis patients. The emergence of vancomycin resistant organisms requires that alternate antibiotics be considered for these infections. Marx and colleagues studied the efficacy and pharmacokinetics of cefazolin given empirically to treat hemodialysis access infections. All 15 infections responded to cefazolin.
Comment: This study shows that cefazolin given after hemodialysis may be effective empiric therapy for access related infections. The study documents that cefazolin kinetics in hemodialysis patients support that treatment would be successful since cefazolin concentrations approximately 3 times the MIC for most pathogens were attained by dosing after dialysis. Although not quite as convenient as the more prolonged dosing possible with vancomycin, the use of cefazolin as empiric treatment may decrease the risk of developing vancomycin resistant organisms. (George R. Aronoff, M.D., University of Louisville, Kentucky)
To go back use the BACK button on your browser. Otherwise click on the desired link to this article below:
ASN 30th Annual Meeting, San Antonio
CRF by problem area : Infections (other than hepatitis, peritonitis)